KONEXMachinery258050

Tech Trans

₩449 0.00%2026-11-18 close
Market Cap
₩7.1B
Turnover
₩0
Volume
0 shares
Shares out.
15.8M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Capital impairment amid a trading halt

Tech Trans has been under a trading halt since March 23, 2026, carrying both capital impairment and a pending delisting decision.

  1. 1

    FY2025 revenue was KRW 298,936,050, down 57.2% from 2024 (based on financial statements and WiseReport).

  2. 2

    The FY2025 operating loss of KRW 816,817,327 and net loss of KRW 814,744,711 were both larger than in 2024.

  3. 3

    Total equity stood at KRW (142,435,722) as of December 31, 2025, indicating capital impairment.

  4. 4

    Trading was suspended on March 23, 2026 for other investor-protection reasons, and an improvement period was granted until a delisting decision.

  5. 5

    A third-party rights issue and conversion of redeemable preferred shares are bringing in funds while increasing the share count.

02

Business structure

Tech Trans is a non-ferrous metal functional surface treatment company founded on April 25, 2011. The company runs three business lines: surface treatment equipment, dedicated electrolytes and surface treatment products, with TAC process technology at its core.

The TAC process forms a protective surface through electrical, physical and chemical treatment, giving materials corrosion resistance, wear resistance, heat resistance and dielectric strength.

In the FY2024 revenue mix, surface treatment equipment accounted for 65.9%, dedicated electrolytes for 13.2% and surface treatment products for 2.1%. Because equipment is the largest share, equipment sales timing has a large effect on results.

The company cites automotive parts, robot-dog leg parts, and medical and massage chair components as application areas. In 2025, fewer surface treatment product orders and weak TAC equipment sales caused revenue to drop sharply. Under this structure, swings in orders pass quickly into revenue.

The disclosures do not give market share figures, and same-sector listed peers include People & Technology and SPG. As of December 31, 2024, the largest holder was CERAGEM International with a 13.46% stake.

03

Recent trends

On the FY2025 financial statements, revenue was KRW 298,936,050, down 57.2% from KRW 698,317,952 in 2024. Over the same period, the operating loss widened to KRW 816,817,327 from KRW 608,006,825 in 2024, and the net loss was KRW 814,744,711.

Gross profit of KRW 225,975,961 in 2024 turned into a gross loss of KRW 26,642,479 in 2025. Selling and administrative expenses fell to KRW 790,174,848 from KRW 830,982,786 but did not offset the revenue decline. R&D expenses charged to expense were KRW 312,856,159 in 2025, close to KRW 313,165,759 in 2024.

According to the company's results commentary, fewer surface treatment product orders, weak TAC equipment sales, fixed-cost burden and higher costs drove the deterioration. Total equity was KRW (142,435,722) as of December 31, 2025, and accumulated deficit reached KRW 13,980,837,975.

On March 23, 2026, trading was suspended for other investor-protection reasons, and a later change notice granted an improvement period. At the March 31, 2026 annual general meeting, three agenda items including approval of financial statements passed.

The last close before the halt, KRW 449, is the displayed price, and turnover is zero during the suspension. Per Investing.com, the 52-week range is KRW 183 to KRW 1,098.

04

Outlook

The nearest turning point is the delisting decision that follows the end of the improvement period. The decision follows KONEX listing rules, and trading remains restricted until it is made. With total equity negative, resolving capital impairment is the central financial checkpoint.

Accumulated deficit of KRW 13,980,837,975 means that loss reduction and capital replenishment would both be needed for the capital structure to recover.

The third-party rights issue of KRW 913.84 million is larger than FY2025 revenue of KRW 298,936,050, with KRW 600 million designated for operating funds and KRW 313.84 million for other purposes.

However, the disclosed conversion of redeemable preferred shares into 2,610,922 common shares will raise the share count and affect per-share metrics. On diversification, whether robot and medical component applications convert into actual revenue is the next point to check. The FY2026 annual report will be the next financial checkpoint.

05

Bull factors

Shareholder-linked rights issue adds operating funds

Per recent reports, Tech Trans decided on a third-party rights issue to raise KRW 913.84 million. The new shares number 2,035,279 common shares, priced at KRW 449, the close on the trading-halt date. Named allottees are Kwon Ki-up and Lee Jeong-sun. About two-thirds of the proceeds, KRW 600 million, is designated for operating funds.

TAC process and expanding application areas

The company holds TAC-process dedicated equipment and dedicated electrolytes as its core technologies. Its annual report lists robot-dog leg parts and medical and massage chair components as application areas.

Because the surface treatment confers corrosion and wear resistance, rising demand for industrial parts could carry through to equipment and electrolyte demand. However, the disclosures do not give specific revenue amounts by application area.

Lower SG&A and sustained R&D

SG&A expenses fell to KRW 790,174,848 in 2025 from KRW 830,982,786 in 2024. R&D expenses charged to expense held at KRW 312,856,159 in 2025, close to KRW 313,165,759 in 2024. Keeping R&D spending steady while revenue fell 57.2% can be read as preserving the technology base. On the cost side, the SG&A reduction partly offsets the widening loss.

06

Bear factors

Three straight years of operating losses and a revenue collapse

Operating losses were KRW 1,205,067,550 in 2023, KRW 608,006,825 in 2024 and KRW 816,817,327 in 2025, a third consecutive year of losses. Revenue fell from KRW 698,317,952 in 2024 to KRW 298,936,050 in 2025. Fewer surface treatment product orders and weak TAC equipment sales were cited as causes. Higher costs combined with fixed-cost burden turned gross profit into a loss.

Negative equity and accumulated deficit

Total equity was KRW (142,435,722) as of December 31, 2025. The accumulated deficit of KRW 13,980,837,975 far exceeds paid-in capital of KRW 1,353,639,900. The FY2025 net loss of KRW 814,744,711 added to that deficit. Capital impairment is a financial issue to be read alongside the trading halt and the improvement period.

Trading halt and a rising share count

Trading has been suspended since March 23, 2026, and remains restricted until the improvement period ends. During the halt, no new market price is formed, so KRW 449 remains only the last pre-halt close.

Conversion of redeemable preferred shares will issue 2,610,922 common shares, and the rights issue has approved 2,035,279 new shares. Existing shareholders face dilution that flows into per-share measures.

07

Risk factors

Macro

Economic cycles in end-demand industries can directly affect orders for surface treatment equipment and electrolytes. Key application areas span cyclical sectors such as automotive parts and medical and massage chair components, so revenue can swing with equipment investment cycles. The results commentary also cited higher costs as a factor in weaker profitability.

Regulatory and listing

Trading is suspended under Article 27 of the KONEX listing rules. A delisting decision follows the end of the improvement period, and its outcome could significantly change whether trading resumes and how shares are distributed.

Because listing review considers financial indicators alongside other criteria, the capital impairment is a key variable.

Dilution and liquidity

Conversion of redeemable preferred shares and the third-party rights issue are increasing the number of shares outstanding. As of December 31, 2024, the largest holder held a 13.46% stake. Per Investing.com, the three-month average volume is about 224 shares, so price formation could be unstable after trading resumes.

08

Overall view

In FY2025, Tech Trans saw revenue collapse and losses widen, leaving it in a state of capital impairment. The larger loss relative to 2024 shows the direction of its financial indicators.

On the positive side, the TAC process and expanding application areas are cited, along with operating funds secured through a rights issue involving major shareholders.

On the negative side, three consecutive years of operating losses, negative total equity, and the trading halt with an improvement period are the core issues. The displayed KRW 449 is the last pre-halt close, so it is hard to read as a current market assessment.

The facts to track are the delisting decision after the improvement period, whether capital impairment is resolved, FY2026 results, and the effect of new share issuance on the share count. This report is an informational summary of facts and issues.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. kind.krx.co.kr
  2. kind.krx.co.kr
  3. comp.wisereport.co.kr
  4. m.news.nate.com
  5. digitaltoday.co.kr
  6. goinsider.kr
  7. m.news.nate.com
  8. digitaltoday.co.kr
  9. digitaltoday.co.kr
  10. investing.com
  11. prestocknews.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis